A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 4
- Study design
- RANDOMIZED · PARALLEL · PREVENTION · QUADRUPLE
- Evidence population
- Human clinical study registration
- Participants
- 9971
- Population
- ALL · 70 Years
- Duration
- 2015-07-01 to 2025-12-01
- Intervention
- Atorvastatin; Placebo (for Atorvastatin)
- Comparator
- Placebo
- Outcomes measured
- Disability free survival - death or development of dementia or development of persistent physical disability — Time fro…; Major cardiovascular events — Time from randomisation to a primary endpoint or censoring at the end of study follow-up…; A composite of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — Time from randomisation to a…; Cardiovascular death — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which…; Fatal and Non-fatal Mycocardial infarction — Time from randomisation to a secondary endpoint or censoring at the end of…; Hospitalisations — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is…; Fatal and Non-fatal Cancer — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up…; Other cognitive impairment — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up…; Quality of life measured by the Short Form Health Survey (SF-36) — Time from randomisation to a secondary endpoint or c…; Cost-effectiveness of statin — Time from randomisation to a secondary endpoint or censoring at the end of study follow-…; Fatal and Non-fatal Stroke — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up…; Approved need for permanent residential care — Time from randomisation to a secondary endpoint or censoring at the end…; Dementia — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is anticipa…; Persistent physical disability — Time from randomisation to a secondary endpoint or censoring at the end of study follo…; All cause death — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is a…; Heart failure — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which is ant…; Atrial fibrillation — Time from randomisation to a secondary endpoint or censoring at the end of study follow-up which…; Revascularisation procedure — Time from randomisation to a secondary endpoint or censoring at the end of study follow-u…
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Disability-free survival · 100%Summary contains controlled topic terminology. Source terminology contains a controlled topic term. Title supplies ageing or longevity context.
Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.